New hope for advanced cancer? early trial of WJB001 begins
NCT ID NCT05773820
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests an experimental drug called WJB001 in people with advanced solid tumors who have no standard treatment options left. The trial has three parts: first, finding a safe dose; second, checking how well that dose works; and third, testing it in specific tumor types. About 210 participants will take WJB001 capsules daily in cycles, with researchers closely monitoring safety and any tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WJB001 capsules
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase I/II trial with only 210 participants. The drug may not work as hoped, and side effects could be serious. Success in this small group may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fuxin People's Hospital (Fuxin Women and Children's Medical Center)
NOT_YET_RECRUITINGFuxin, Liaoning, 123000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henan Cancer Hospital
RECRUITINGHenan, Zhenzhou, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Liaoning Cancer Hospital
RECRUITINGShenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, Shanxi, 030000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi 'an Jiaotong University
RECRUITINGXi’an, Shanxi, 710061, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tumor Hospital Affiliated to Guangxi Medical University
RECRUITINGNanning, Guangxi, 530000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430023, China
Contact Phone: •••-•••-•••• Email: •••••@•••••